Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Entrada Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of intracellular therapeutics that enable the delivery of biologic medicines inside cells. The company operates within the biotechnology and pharmaceutical research and development industries, with a core emphasis on diseases caused by the absence or dysfunction of intracellular proteins. Its primary revenue drivers are research and development activities related to proprietary therapeutic candidates rather than commercial product sales, as the company has no approved products as of the most recent public disclosures.
The company’s core strategic advantage is its proprietary Endosomal Escape Vehicle (EEV™) platform, which is designed to enable the intracellular delivery of proteins, antibodies, and other biologic modalities previously unable to cross the cell membrane. Entrada was founded in 2016 and has evolved from a platform-focused research company into a clinical-stage organization advancing multiple therapeutic programs, including candidates targeting Duchenne muscular dystrophy (DMD) and other genetic neuromuscular and immunological disorders.
Business Operations
Entrada operates as a single-reportable-segment biotechnology company, with substantially all activities focused on research and development. Its operations center on the discovery, preclinical development, and clinical evaluation of intracellular biologic therapeutics built on the EEV™ platform, which enables systemic delivery of functional proteins into target tissues. The company does not currently generate revenue from product sales and relies primarily on equity financing and cash reserves to fund operations.
Operations are conducted through the parent entity, Entrada Therapeutics, Inc., and its wholly owned subsidiaries, including Entrada Therapeutics (UK) Ltd, which supports research and development activities. The company maintains internal discovery and translational capabilities and collaborates with contract research organizations for clinical trials, manufacturing, and specialized testing. As of public filings, Entrada has not disclosed material revenue-generating partnerships, joint ventures, or commercial licensing arrangements.
Strategic Position & Investments
Entrada’s strategic direction centers on advancing a pipeline of intracellular protein replacement and modulation therapies toward clinical proof of concept. A key growth initiative is the development of EEV-conjugated therapeutic proteins for genetic diseases such as DMD, where restoring intracellular protein function represents a differentiated therapeutic approach. The company continues to invest heavily in expanding and validating the EEV™ platform across multiple biologic payloads and disease indications.
Rather than pursuing large-scale acquisitions, Entrada’s investments have focused on internal research capabilities, intellectual property development, and progression of clinical-stage assets. Its pipeline includes multiple wholly owned development candidates derived from its platform technology, with no publicly disclosed material acquisitions of external companies. The company is positioned within the emerging field of intracellular biologics, a sector viewed as complementary to, but distinct from, traditional gene therapy and small-molecule approaches.
Geographic Footprint
Entrada is headquartered in the United States, with its principal executive offices in Boston, Massachusetts, a major global biotechnology hub. The company conducts the majority of its strategic management, research planning, and corporate functions from this location.
Internationally, Entrada maintains a presence in the United Kingdom through Entrada Therapeutics (UK) Ltd, which supports research and development activities and access to international scientific talent. While clinical trials may be conducted across multiple regions depending on study design, the company’s operational footprint is primarily concentrated in North America and Europe, with no disclosed commercial operations in other regions.
Leadership & Governance
Entrada was founded by academic scientists with expertise in chemistry and drug delivery, and it is led by an executive team with backgrounds spanning biotechnology research, clinical development, and corporate strategy. The leadership emphasizes disciplined platform development, rigorous clinical validation, and long-term value creation through wholly owned assets rather than near-term commercialization.
Key executives include:
- Dipal Doshi, PhD – President and Chief Executive Officer
- Mark McKenna – Chief Financial Officer
- Viviana Gradinaru, PhD – Co-Founder and Scientific Advisor
- David Mendel, MD, PhD – Chief Medical Officer
The company is governed by a board of directors that includes experienced biotechnology executives and scientific leaders, reflecting a governance philosophy centered on innovation, scientific rigor, and responsible capital allocation.